When I eventually got a bed it was usually in a ward full of elderly patients with various stages of Alzheimer’s. Each visit was a repeat ... private care homes will not be well pleased - but the NHS ...

Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.

The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday, October 23, that it ...

UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease: Indianapolis Thursday, October 24, 2024, 09:0 ...

The UK's drug regulator granted approval for Kisunla, an Alzheimer's medication, while an independent assessment body rejected its NHS funding on grounds of cost. The approval marks the second ...

Donanemab has been hailed as 'game changer' but the price tag has barred it from being available to nearly one million Brits.

A pioneering new drug, which has been shown to slow the advance of Alzheimer's, will not be available to patients on the NHS as Ian Woods reports. A new "effective" Alzheimer's drug has been rejected ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab has already been rejected in the NHS in England but Scottish Medicines Consortium has still to make a decision on ...

The announcement comes as the UK's medicines regulator said that donanemab could be licensed for use in the UK.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...